NCT03820141View on ClinicalTrials.gov

Durvalumab with Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

39

Participants

Timeline

Start Date

March 3, 2020

Primary Completion Date

October 30, 2024

Study Completion Date

December 31, 2025

Conditions

Breast Cancer

Interventions

DRUG

Durvalumab

programmed cell death-ligand 1 inhibitor

DRUG

Trastuzumab

anti-HER2 monoclonal antibody

DRUG

Pertuzumab

anti-HER2 monoclonal antibody

Trial Locations (1)

77030

Houston Methodist Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

The Methodist Hospital Research Institute

OTHER